Clinical Cancer Research

Papers
(The H4-Index of Clinical Cancer Research is 65. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Selected Articles from This Issue445
Selected Articles from This Issue263
Selected Articles from This Issue247
Rewiring Antitumor Immunity: Targeting CLDN18.2 with Conditional 4-1BB Activation229
Abstract C025: Endometrial cancer mutation patterns by age with possible increased TP53 and decreased PTEN mutations in patients 50+ years old219
CH Mutations in 16,812 Advanced Cancer Patients–Response206
Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study185
Abstract B036: Non-steroidal anti-inflammatory drugs use and risk of colorectal cancer molecular subtypes: A systematic review and meta-analysis179
One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication175
A Cohort Study of CNS Tumors in Multiple Endocrine Neoplasia Type 1169
NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer150
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer145
An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer144
Abstract PS1-10-18: Genomic analysis of ER+/HER2- metastatic invasive lobular carcinoma (ILC) and clinical outcomes comparison with metastatic invasive carcinoma of no special type (NST)134
Project Optimus Elicits the “Holistic” Benefits of PK/PD Modeling of Immunotherapy127
Optimizing ATR Inhibition and Cisplatin Synergy in Ewing Sarcoma125
Abstract PS2-07-19: Proteomic subtyping of stage II/III TNBC from the I-SPY2 TRIAL reveals a druggable steroid hormone receptor signature (SRS) that is associated with poor outcome and enriched in non120
Abstract PS2-08-09: Baseline HER2 expression on circulating tumor cells in metastatic breast cancer119
Abstract PS1-13-04: Fairness-constrained logistic regression achieves superior performance and racial equity in breast cancer survival prediction114
Abstract PS2-04-10: Adherence to endocrine prevention in patients with atypical hyperplasia and lobular carcinoma in situ: promising trends from real-world use of low dose tamoxifen112
Abstract PS2-07-21: Tumor Necrosis Factor-related Weak Inducer of Apoptosis (TWEAK) - A Potential Biomarker for Predicting Response and Long-Term Outcomes in Early Breast Cancer Patients111
Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-Based Tests for Early Cancer Detection109
Abstract PS3-03-18: Guidelines for Breast Cancer Index Test before and after Epic software enhancement103
Abstract PS2-10-18: Epithelial-mesenchymal transition (EMT) Signature Score of a Bulk Tumor May Not Reflect the EMT of Malignant Epithelial Cells103
Abstract PS3-07-12: The CONCISE Study : A Pan-UK Real-World Audit of Adjuvant Abemaciclib Use in High-Risk Early Breast Cancer101
Selected Articles from This Issue100
Abstract PS5-10-21: Real-world patterns and preferences in the use of diagnostic imaging for breast cancer staging in Hispano-America: A multinational physician survey100
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer99
Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma95
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research92
Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality91
Learning Individual Survival Models from PanCancer Whole Transcriptome Data91
Abstract RF2-06: Impact of Immune Checkpoint Inhibition (CPI) on Fertility in Young Women with Early Triple-Negative Breast Cancer (TNBC) receiving neoadjuvant Chemotherapy (NACT): A Prospective Subst89
Abstract PS5-12-26: Yoga in Breast Cancer Survivorship: Knowledge, Attitudes, <Perceived Benefits88
Abstract PS5-08-15: Targeted axillary dissection vs axillary node clearance in patients with positive axillary nodes in early breast cancer: a multicentre, pragmatic, phase 3 randomised controlled tri85
Abstract PS5-05-25: Is the 21-Gene Recurrence Score Validated for Real-World use in Node Positive Breast Cancer? A Retrospective Cohort Study85
Abstract PS5-12-10: Impact of KEYNOTE-522 on BneoCT: An Institutional Quality Measure Improvement Analysis84
Abstract PS5-07-29: Trial in progress: a phase 1 dose-escalation study evaluating BGB-21447 (BCL2 inhibitor) in combination with fulvestrant with and without BGB-43395 (CDK4 inhibitor) in patients wit83
Abstract PS5-12-05: Cdk4/6 inhibitors in outpatient gynecological oncology: identification of implementation barriers and opportunities for improving their use in the practice83
Abstract PS4-02-26: Gper signaling as a biomarker for endocrine therapy sensitivity in pik3ca mutant hr+ advanced breast cancer83
PS4-05-22: Eprs1 induces ac4c modification of mRNAs encoding pluripotency factors in breast cancer cells82
Abstract PS1-13-10: Elucidating Stemness-Associated Regulatory Pathways to Guide Personalized Treatment for Ductal Carcinoma in Situ82
Abstract PS4-02-09: Symptom Clustering and Multi-Omics Signatures of Cancer-Related Fatigue in Breast Cancer: Findings from the China PERSEVERE Cohort81
Abstract PS2-01-07: A Multicenter Retrospective Observational Study on the Safety and Timing of Radiotherapy After Oncoplastic Breast-Conserving Surgery81
Abstract PS2-05-06: Safety and Oncologic Outcomes of Immediate Breast Reconstruction Following Neoadjuvant Chemotherapy80
Abstract PS3-11-18: Neoadjuvant Response in HER2+ Early Breast Cancer: A Comparative Study Between HER2-Enriched and Luminal HER2 Subtypes80
Abstract PS3-11-13: Fatty Acid Profile and Its Association with HER2-Positive Breast Cancer and Response to Neoadjuvant Chemotherapy78
Abstract PS4-04-30: Discovery of NKT5097: a first-in-class, highly potent and selective, orally bioavailable CDK2/4 dual degrader for cancer therapy77
Abstract PS4-05-03: Pro-c3 as a circulating biomarker of tumor fibrosis in breast cancer: functional insights from studying cancer associated fibroblasts in vitro77
Abstract PS4-06-19: Final results of a Phase I trial of an alpha-lactalbumin (aLA) vaccine for breast cancer75
Abstract PS1-11-18: Prescription Patterns and Treatment Persistence in Patients with Metastatic Breast Cancer on CDK4/6 Inhibitors75
Abstract PS1-08-07: Final results from the Randomized Phase II study of Z-Endoxifen and Tamoxifen in Endocrine Refractory, Estrogen Receptor Positive, HER2 negative Metastatic Breast Cancer (Alliance 74
Abstract PS1-06-27: The Use of Contrast Enhanced Mammography for Noncalcified Ductal Carcinoma Insitu for the Breast: Pre Surgical Staging and Planning73
Abstract PS3-02-06: Stromal-Fibroblastic remodelling and involution signatures in non-tumoral tissue of postpartum breast cancer patients: implications for breast cancer risk71
Abstract PS3-02-03: Leucine-rich repeat neuronal 1 as a prognostic indicator and functional modulator in breast cancer69
Abstract PS5-06-25: Investigating association of comorbidities and race with all-cause mortality outcomes of PI3K inhibitor use in metastatic breast cancer (mBC)68
Abstract PS4-08-29: Neoadjuvant antibody-drug conjugates for early-stage breast cancer: a systematic review and meta-analysis67
PS5-06-22: Atypical recurrence of invasive lobular breast carcinoma with hormone receptor loss: a Case Report67
Abstract PS2-02-01: Improved Antiemetic Outcomes with NEPA vs (Fos)aprepitant in Patients with Breast Cancer Receiving Antibody-Drug Conjugates: A 12-Month Real-World Claims Analysis66
Abstract PS4-08-25: Trends and determinants of non-treatment in early-stage breast cancer (ESBC)66
Abstract PS4-08-06: Optimizing Postoperative Adjuvant Therapy for Early-Stage Breast Cancer by Combining Dynamic ctDNA MRD Monitoring with Clinical Risk Stratification: An Open-label, Multicenter, Pro66
Abstract PS2-02-21: Real-world outcomes of CDK4/6 inhibitors in patients with metastatic invasive lobular carcinoma: a retrospective single-center study66
Abstract PS3-05-14: Clinical significance of pathogenic variants in breast cancer patients at risk for hereditary breast cancer66
Abstract PS2-07-13: Prognostic and predictive role of RBsig and CCNE1/RB1 gene-expression signatures for patients with early breast cancer treated with endocrine therapy with or without palbociclib in65
Abstract PS2-12-04: Promoter Hypermethylation-Induced Silencing of FXYD1 Drives Breast Cancer Metastasis via DDX5-Mediated Wnt/β-Catenin Pathway Activation65
Abstract PS4-06-09: Efficacy of a novel BCL-xL degrader, DT2216, in the treatment of triple-negative breast cancer65
0.28981399536133